We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC Orders Baxter to Divest Rights to Two Drugs as Part of Claris Takeover
FTC Orders Baxter to Divest Rights to Two Drugs as Part of Claris Takeover
Baxter International will divest the rights to two drugs held by Claris Lifesciences to offset the anticompetitive effects of its acquisition of Claris, under terms of a final FTC order.